Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensifentrine - Verona Pharma

Drug Profile

Ensifentrine - Verona Pharma

Alternative Names: RPL 554

Latest Information Update: 04 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vernalis
  • Developer Verona Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antibronchitics; Antifibrotics; Imines; Isoquinolines; Small molecules; Urea compounds
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Chronic obstructive pulmonary disease
  • Phase II Asthma; Bronchiectasis; Cystic fibrosis
  • Phase I Allergic asthma
  • Discontinued Allergic rhinitis; COVID 2019 infections

Most Recent Events

  • 29 Feb 2024 Verona Pharma with Nuance Pharma announces intention to launch nebulized ensifentrine for Chronic obstructive pulmonary disease in China, Hong Kong, Macau, Taiwan
  • 11 Dec 2023 Phase-II clinical trials in Bronchiectasis (Inhalation) before December 2023 (Verona Pharma pipeline, December 2023)
  • 09 Nov 2023 Verona Pharma plans a phase II trial for Bronchiectasis at unknown location (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top